Named Bioactive Compounds · Compound
Picroside II (Iridoid Glycoside)
Moderate Evidenceother_bioactives
Hermetica Superfood Encyclopedia
Picroside II is an iridoid glycoside compound found primarily in Picrorhiza kurroa that demonstrates protective effects on kidney and liver function. The compound works through anti-inflammatory pathways and antioxidant mechanisms to reduce cellular damage in various organ systems.
Picroside II is an iridoid glycoside extracted from the roots of Picrorhiza scrophulariiflora (Kutki), a plant used in traditional medicine. It is a naturally occurring monoterpenoid glycosidically bound to glucose, obtained through extraction processes from the plant's rhizomes or roots.
No human clinical trials, RCTs, or meta-analyses have been conducted on Picroside II. All available evidence comes from preclinical animal models including mouse sepsis studies (n=30) showing improved survival rates, and renal injury models demonstrating reduced inflammatory markers.
No human dosage data is available. Animal studies used 20 mg/kg administered intraperitoneally or intravenously in mouse models. Consult a healthcare provider before starting any new supplement.
Picroside II (also known as cucurbitacin B glucoside or 6-vanilloyl catalpol) is a purified iridoid glycoside compound, not a food or dietary supplement with a broad nutritional profile. Key details: • Molecular formula: C23H28O13; Molecular weight: ~512.46 g/mol • It is a single bioactive compound isolated primarily from Picrorhiza kurroa (kutki) rhizomes and occasionally from Picrorhiza scrophulariiflora • Contains an iridoid (catalpol-type) backbone esterified with a vanilloyl (4-hydroxy-3-methoxybenzoyl) moiety at C-6, linked to a glucose sugar unit • No macronutrients (protein, fat, carbohydrate, fiber) in any meaningful dietary sense, as it is used in microgram-to-milligram research doses • No vitamins or minerals intrinsic to the compound • Bioactive concentration: In raw Picrorhiza kurroa rhizome, picroside II typically constitutes approximately 1.5–3.5% w/w of dried rhizome extract; standardized commercial extracts (e.g., Picroliv) are often standardized to contain ~33% picroside II alongside ~23% picroside I (kutkoside) • Bioavailability notes: Oral bioavailability in rodent models is estimated to be low-to-moderate (~20–35%), with rapid first-pass hepatic metabolism; the compound undergoes hydrolysis by intestinal and hepatic esterases, releasing the vanillic acid moiety and catalpol aglycone; the glucose moiety enhances water solubility (LogP approximately −0.5 to 0.3) relative to the aglycone; plasma half-life in rats is reported at approximately 1.5–3 hours after oral administration; co-administration with lipid-based carriers or nanoformulations has shown 2–3 fold improvement in bioavailability in preclinical studies • Key pharmacologically relevant functional groups: phenolic hydroxyl (antioxidant activity), iridoid ring system (anti-inflammatory signaling), and glycosidic bond (influences solubility and gut absorption kinetics)
Picroside II modulates inflammatory cascades by inhibiting pro-inflammatory cytokines including TNF-α and IL-6 while enhancing antioxidant enzyme activity. The compound appears to protect cellular membranes through free radical scavenging and may influence NF-κB signaling pathways. Its neuroprotective effects involve reducing oxidative stress markers and supporting mitochondrial function in neural tissues.
Research on picroside II consists primarily of animal studies and in vitro experiments, with limited human clinical data available. Mouse models demonstrate 50% survival improvement in sepsis studies at 20 mg/kg dosage, while kidney protection studies show improved renal microcirculation and reduced inflammation markers. Neuroprotective research indicates potential benefits against Alzheimer's-related pathology in preliminary animal models. Human clinical trials are needed to establish safety profiles and effective dosing protocols for therapeutic applications.
Safety data for picroside II in humans remains limited due to lack of comprehensive clinical trials. Animal studies suggest the compound is generally well-tolerated at research dosages, but long-term safety profiles have not been established. Potential interactions with medications metabolized by liver enzymes remain unknown and require further investigation. Pregnant and breastfeeding women should avoid picroside II supplementation due to insufficient safety data.
